RWE and HTA: a snapshot of recent developments with Sreeram Ramagopalan – June–July 2021

8 Sep 2021

Written by Sreeram Ramagopalan (F. Hoffmann-La Roche)

Decision science Guest columns Health technology assessment Industry Updates Journal articles Oncology and hematology Real-world evidence

Read highlights from the latest instalment of Sreeram Ramagopalan’s (F. Hoffmann-La Roche, Basel, Switzerland) industry news round-up, which discusses some of the latest developments in real-world evidence (RWE) in the context of health technology assessment (HTA) and is published bi-monthly in our partner journal, the Journal of Comparative Effectiveness Research. Read the full update for June–July 2021 in the Journal of Comparative Effectiveness Research here >>> What happened over these months that you were expecting? I was expecting some readouts from the I-O Optimise initiative led by Bristol Myers Squibb (NY, USA), characterizing lung cancer using data sources from across...